| 1 |
35112436 | Suppression of non-small-cell lung cancer A549 tumor growth by an mtDNA mutation-targeting pyrrole-imidazole polyamide-triphenylphosphonium and a senolytic drug. | 2022 Apr |
1 |
| 2 |
35172148 | BCL-XL inhibition induces an FGFR4-mediated rescue response in colorectal cancer. | 2022 Feb 15 |
3 |
| 3 |
33859162 | Malignant pleural mesothelioma co-opts BCL-XL and autophagy to escape apoptosis. | 2021 Apr 15 |
3 |
| 4 |
33980597 | Selective BCL-XL Antagonists Eliminate Infected Cells from a Primary-Cell Model of HIV Latency but Not from Ex Vivo Reservoirs. | 2021 Jul 12 |
1 |
| 5 |
34141086 | Structure-Based Design of A-1293102, a Potent and Selective BCL-XL Inhibitor. | 2021 Jun 10 |
1 |
| 6 |
34734676 | Dexmedetomidine attenuates propofol-induced apoptosis of neonatal hippocampal astrocytes by inhibiting the Bcl2l1 signalling pathway. | 2021 Dec |
2 |
| 7 |
32708132 | DLBCL Cells with Acquired Resistance to Venetoclax Are Not Sensitized to BIRD-2 But Can Be Resensitized to Venetoclax through Bcl-XL Inhibition. | 2020 Jul 21 |
1 |
| 8 |
33062160 | Discovery of A-1331852, a First-in-Class, Potent, and Orally-Bioavailable BCL-XL Inhibitor. | 2020 Oct 8 |
1 |
| 9 |
28273655 | New agents that target senescent cells: the flavone, fisetin, and the BCL-XL inhibitors, A1331852 and A1155463. | 2017 Mar 8 |
1 |
| 10 |
26939706 | Expression Profile of BCL-2, BCL-XL, and MCL-1 Predicts Pharmacological Response to the BCL-2 Selective Antagonist Venetoclax in Multiple Myeloma Models. | 2016 May |
2 |
| 11 |
26565405 | Loss in MCL-1 function sensitizes non-Hodgkin's lymphoma cell lines to the BCL-2-selective inhibitor venetoclax (ABT-199). | 2015 Nov 13 |
1 |
| 12 |
25313317 | Discovery of a Potent and Selective BCL-XL Inhibitor with in Vivo Activity. | 2014 Oct 9 |
1 |